A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD - Full Text View

Sponsored by:	Pfizer
Information provided by:	Pfizer
ClinicalTrials.gov Identifier:	NCT00163098

Purpose

A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD

Condition	Intervention	Phase
Pulmonary Disease, Chronic Obstructive	Drug: UK-369,003	Phase I Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Multi-Centre, Multinational, Randomized, Double-Blind, Placebo Controlled, Proof Of Concept Trial To Assess The Effects Of A Subject-Optimized Dose Of UK-369,003 On Exercise Capacity In Subjects With Chronic Obstructive Pulmonary Disease

Further study details as provided by Pfizer:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	136
Study Start Date:	December 2004
Estimated Study Completion Date:	December 2005

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00163098

Sponsors and Collaborators

Pfizer

Investigators

Study Director:

Pfizer CT.gov Call Center

Pfizer

More Information

Study ID Numbers:	A3711028
Study First Received:	September 8, 2005
Last Updated:	October 12, 2006
ClinicalTrials.gov Identifier:	NCT00163098
Health Authority:	Germany: Ethics Commision

Study placed in the following topic categories:

Lung Diseases, Obstructive
Respiratory Tract Diseases
Lung Diseases

Respiration Disorders
Chronic Disease
Pulmonary Disease, Chronic Obstructive

Additional relevant MeSH terms:

Disease Attributes
Pathologic Processes

ClinicalTrials.gov processed this record on January 15, 2009